Is There Any Improvement of the Coagulation Imbalance in Sickle Cell Disease After Hematopoietic Stem Cell Transplantation?

Overview

Journal J Clin Med

Specialty General Medicine

Date 2019 Nov 14

PMID 31717804

Citations 2

Authors

Laurence Rozen

Denis F Noubouossie

Laurence Dedeken

Phu Quoc Le

Alina Ferster

Anne Demulder

Affiliations

Soon will be listed here.

Abstract

Several components of the clotting system are modified towards hypercoagulability in sickle cell disease (SCD). To date, hematopoietic stem cell transplantation (HSCT) is the only validated curative treatment of SCD. Here, we investigated the changes in the hemostatic potential of SCD children who've received a successful HSCT. Seventeen children with severe SCD were enrolled in the study. Thrombin generation (TG) was performed on citrated platelet-poor plasma, obtained before and 3, 6, 9, 12 and 15 months after HSCT. TG was triggered using 1 pM tissue factor and 4 µM phospholipids with or without thrombomodulin (TM). Before the HSCT, SCD children showed a higher endogenous thrombin potential (ETP), higher peak, higher velocity and shorter time-to-peak of TG than the normal controls (NC). ETP did not significantly change following the HSCT. However, the peak, velocity and time-to-peak of TG reversed to normal ranges from 3 months post-HSCT and remained so up to 15 months post-HSCT. The reduction of ETP after the addition of thrombomodulin (RETP) was dramatically reduced in SCD children before HSCT as compared with the NC. A partial reversal of RETP was observed from 3 months through 15 months post-HSCT. No statistical difference was observed for patient age or donor hemoglobinopathy status. In summary, successful HSCT improves the kinetics of TG but not the total thrombin capacity in SCD children.

Citing Articles

Applicability of the Thrombin Generation Test to Evaluate the Hemostatic Status of Hemophilia A Patients in Daily Clinical Practice.

Bernardo A, Caro A, Martinez-Carballeira D, Corte J, Vazquez S, Palomo-Antequera C J Clin Med. 2022; 11(12).

PMID: 35743412 PMC: 9224793. DOI: 10.3390/jcm11123345.

Time to rethink haemoglobin threshold guidelines in sickle cell disease.

Ballas S, Kuypers F, Gordeuk V, Hankins J, Thompson A, Vichinsky E Br J Haematol. 2021; 195(4):518-522.

PMID: 34131897 PMC: 9292304. DOI: 10.1111/bjh.17578.

References

van Tits L, van Heerde W, Landburg P, Boderie M, Muskiet F, Jacobs N . Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochem Biophys Res Commun. 2009; 390(1):161-4. DOI: 10.1016/j.bbrc.2009.09.102. View

Noubouossie D, Le P, Rozen L, Debaugnies F, Ferster A, Demulder A . Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays. Thromb Res. 2011; 130(2):259-64. DOI: 10.1016/j.thromres.2011.10.016. View

Tripodi A . Detection of procoagulant imbalance. Modified endogenous thrombin potential with results expressed as ratio of values with-to-without thrombomodulin. Thromb Haemost. 2017; 117(5):830-836. DOI: 10.1160/TH16-10-0806. View

Westerman M, Pizzey A, Hirschman J, Cerino M, Weil-Weiner Y, Ramotar P . Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol. 2008; 142(1):126-35. DOI: 10.1111/j.1365-2141.2008.07155.x. View

Rozen L, Noubouossie D, Dedeken L, Huybrechts S, Le P, Ferster A . Different profile of thrombin generation in children with acute lymphoblastic leukaemia treated with native or pegylated asparaginase: A cohort study. Pediatr Blood Cancer. 2016; 64(2):294-301. DOI: 10.1002/pbc.26228. View

Hemker H, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R . Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003; 33(1):4-15. DOI: 10.1159/000071636. View

Noubouossie D, Le P, Corazza F, Debaugnies F, Rozen L, Ferster A . Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children. Am J Hematol. 2011; 87(2):145-9. DOI: 10.1002/ajh.22206. View

Dielis A, Castoldi E, Spronk H, van Oerle R, Hamulyak K, ten Cate H . Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost. 2007; 6(1):125-31. DOI: 10.1111/j.1538-7836.2007.02824.x. View

Roberts L, Patel R, Chitongo P, Bonner L, Arya R . African-Caribbean ethnicity is associated with a hypercoagulable state as measured by thrombin generation. Blood Coagul Fibrinolysis. 2012; 24(1):40-9. DOI: 10.1097/MBC.0b013e32835a07fa. View

10.

White R, Zhou H, Murin S, Harvey D . Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost. 2005; 93(2):298-305. DOI: 10.1160/TH04-08-0506. View

11.

Ataga K, Key N . Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program. 2007; :91-6. DOI: 10.1182/asheducation-2007.1.91. View

12.

Yee D, Edwards R, Mueller B, Teruya J . Thromboelastographic and hemostatic characteristics in pediatric patients with sickle cell disease. Arch Pathol Lab Med. 2005; 129(6):760-5. DOI: 10.5858/2005-129-760-TAHCIP. View

13.

White R, Zhou H, Gage B . Effect of age on the incidence of venous thromboembolism after major surgery. J Thromb Haemost. 2004; 2(8):1327-33. DOI: 10.1046/j.1538-7836.2004.00848.x. View

14.

Noubouossie D, Le P, Rozen L, Ziereisen F, Willems D, Demulder A . Thrombin generation in children with sickle cell disease: relationship with age, hemolysis, transcranial Doppler velocity, and hydroxyurea treatment. Eur J Haematol. 2013; 91(1):46-54. DOI: 10.1111/ejh.12113. View

15.

Rosenthal J . Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment. J Blood Med. 2016; 7:181-6. PMC: 5015877. DOI: 10.2147/JBM.S102235. View

16.

Cappelli B, Volt F, Tozatto-Maio K, Scigliuolo G, Ferster A, Dupont S . Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease. Haematologica. 2019; 104(12):e543-e546. PMC: 6959194. DOI: 10.3324/haematol.2019.216788. View

17.

Whelihan M, Lim M, Mooberry M, Piegore M, Ilich A, Wogu A . Thrombin generation and cell-dependent hypercoagulability in sickle cell disease. J Thromb Haemost. 2016; 14(10):1941-1952. DOI: 10.1111/jth.13416. View

18.

Bayazit A, Kilinc Y . Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state. Pediatr Int. 2001; 43(6):592-6. DOI: 10.1046/j.1442-200x.2001.01476.x. View

19.

Wright J, Malia R, Cooper P, Thomas P, Preston F, Serjeant G . Protein C and protein S in homozygous sickle cell disease: does hepatic dysfunction contribute to low levels?. Br J Haematol. 1997; 98(3):627-31. DOI: 10.1046/j.1365-2141.1997.2663083.x. View

20.

Langstrom S, Koskenvuo M, Huttunen P, Lassila R, Taskinen M, Ranta S . Haematopoietic Stem Cell Transplantation in Children Shifts the Coagulation System towards a Pro-Coagulant State. Thromb Haemost. 2018; 118(8):1390-1396. DOI: 10.1055/s-0038-1661394. View